BIA
ALXO icon

Bell Investment Advisors’s ALX Oncology ALXO Stock Holding History

Bell Investment Advisors’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-88
Closed -$992 – 1913
2022
Q4 		$992 Hold
88
– – ﹤0.01% 1596
2022
Q3 		$1K Hold
88
– – ﹤0.01% 1300
2022
Q2 		$1K Buy
+88
New +$958 ﹤0.01% 1310

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Bell Investment Advisors's ALXO Position: Q1 2023 in Review

Bell Investment Advisors sold out of ALX Oncology (ALXO) in Q1 2023, closing a stake of 88 shares — an estimated $992 sold.

Bell Investment Advisors first reported a position in ALXO in Q2 2022 and held it in 3 quarters. The position peaked at $1K in Q3 2022. 86 funds tracked by Wall St. Rank hold ALXO as of Q1 2023.

  • Bell Investment Advisors reported no remaining ALX Oncology position as of Q1 2023 after selling out during the quarter.
  • Bell Investment Advisors sold 88 ALX Oncology shares in Q1 2023, an estimated $992.
  • Bell Investment Advisors first reported a position in ALX Oncology in Q2 2022 and held it in 3 quarters.
  • Bell Investment Advisors's ALX Oncology position peaked at $1K in Q3 2022.
  • 86 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2023.

Based on Bell Investment Advisors's 13F filing for Q1 2023, filed 10 May 2023.